• Skip to content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Alcohol Flush Blog

The World's Largest Alcohol Flushing Resource

Header Right

  • Alcohol Flush News
  • Learning Center
  • DIY Alcohol flush remedies
  • Product Reviews
  • Drink alcohol with no flushing?
You are here: Home / Flush News / What is the release date of Convivia by Horizon Pharma?

What is the release date of Convivia by Horizon Pharma?

February 23, 2017 Leave a Comment

horizon pharma conference

Since 2007 the much anticipated pharmaceutical answer to alcohol flush reaction called Convivia has changed hands like a hot potato.  Originally developed by Convivia Inc and later acquired by Raptor Pharmaceutical, the promising yet allusive technology now finds itself in the hands of Horizon Pharma after their acquisition of Raptor Pharmaceutical in October 2016.  But all mergers and acquisitions aside, the question we’ve all been asking for the past 10 year remains unanswered – when will Convivia be released to the market?

Unfortunately the answer is unclear to say the least.  What we do know is that in 2008 Raptor Pharmaceutical initiated a phase IIa clinical trial for Convivia.  Phase IIa clinical studies are aimed at establishing a scientific basis for the efficacy of the drug being tested.  In the case of Convivia, it was later that year that they announced positive phase IIa clinical trial results stating that:

The study results demonstrated that the active ingredient in Convivia(TM) significantly reduced heart palpitations (tachycardia), which are commonly experienced by ALDH2 deficient people who drink, at all dose levels tested. The study also found that the 4-MP significantly reduced peak acetaldehyde levels and total acetaldehyde exposure in a subset of the study participants who possess specific genetic variants of the liver ADH and ALDH2 enzymes.

According to these phase IIa results it appears that Convivia was successful reducing acetaldehyde and addressing tachycardia, i.e. the increased heart rate commonly reported by people who suffer from alcohol flush reaction.  Whilst this might sound positive at a glance, it is worth noting that they make no mention of its efficacy in addressing the issue of erythema, i.e. the red flushing commonly experienced on the face, neck and upper body.

One possibility for this omission could be the relative ease of measuring a test subject’s heart rate as compared to the degree of blood vessel dilation and resulting redness of their skin.  However, another explanation could be that it didn’t reduce acetaldehyde levels enough to have a noteworthy effect on facial and upper body redness – the bottom line is we don’t know.

Despite this, in 2010 Raptor Pharmaceutical announced that it had entered into an exclusive licensing agreement with Uni Pharma Co to commercialise Convivia in Taiwan.  In their press release they stated:

Uni Pharma will register Convivia for drug licensure for existing indications and will conduct a clinical trial and register Convivia for acetaldehyde toxicity resulting from ALDH2 deficiency.

7 years later and we haven’t seen Convivia anywhere on the market in the english speaking world, nor do we have any evidence of it being available in Taiwan.  One possible explanation could be that it is in fact being sold in Taiwan and we can’t access the online stores due to language barriers.  Another explanation could be that Uni Pharma ran into some road blocks, either in the clinical trial stage or with regulatory licensing – again unfortunately we don’t know.

What we do know is that the licensing agreement with Uni Pharma covers solely Taiwan and an option to expand into South Korea under the same terms.  What this means is that in the 7 years since the licensing agreement Raptor Pharmaceutical has not progressed the clinical program to Phase III, nor has it made any successful attempts at securing licensing deals outside of Taiwan and South Korea.

With the completed acquisition of Raptor Pharmaceutical by Horizon Pharma, the ball is now in their court as to how they go about bringing Convivia to market in the rest of the world.  Do you think Horizon Pharma will look to fast track Convivia in light of it’s huge potential? Or will it get lost amongst all of their other projects for the next 10 years?  Only time will tell.

We’d love to hear your thoughts and opinions in the comments below.

Filed Under: Flush News Tagged With: alcohol flush reaction, convivia, products

Primary Sidebar

Want some FREE flush-friendly cocktail recipes?

flushed cocktail guide cover

Enter your email below to download your FREE cocktail samples now.

  • Email
  • Facebook
  • Twitter

Flush News

What is the release date of Convivia by Horizon Pharma?

What is the release date of Convivia by Horizon Pharma?

February 23, 2017 By Flush Team

New alcohol flushing cream rumoured to be in the making

New alcohol flushing cream rumoured to be in the making

February 21, 2017 By Flush Team

NIH warns Asian flush sufferers of cancer risk

NIH warns Asian flush sufferers of cancer risk

February 20, 2017 By Flush Team

Tags

acetaldehyde alcohol flush reaction aldh2 enzyme antacids asian flush cancer convivia cream makeup NAC nih pepcid products remedy zantac

Footer

Flush

We are a small community of bloggers who's common ground becomes apparent whenever we all catch up for a drink - our faces turn red! This is why we have combined our resources to put together a reliable and up to date source of information about alcohol flush reaction so that readers can stay up to date with the latest news about this embarrassing condition.

Find out more about us.

Recent

  • Can Pepcid AC Stop Alcohol Flush Reaction?
  • Makeup Tricks to Avoid Alcohol Flushing
  • Can NAC Prevent Alcohol Flush Reaction?
  • What is Alcohol Flush Reaction?
  • What is the release date of Convivia by Horizon Pharma?

Search

Connect

  • Email
  • Facebook
  • Twitter

Copyright © 2018 · Flush